These insights reveal the nuanced interplay between GFPT2 and the NF-κB pathway in regulating ovarian cancer cells’ sensitivity to paclitaxel, presenting the pathway’s modulation by GFPT2 as a promising avenue for therapeutic strategies in ovarian cancer treatment. This evidence concerns the gene NFKB1 and ovarian cancer.